Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
Excalia
HSMN NewsFeed - 15 Dec 2015
eFFECTOR Therapeutics Appoints Alana McNulty Chief Financial Officer
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 21 Nov 2013
Lithera Announces Appointment of Dermatology and Aesthetics Authority Dr. Lincoln Krochmal as Chief Medical Officer
Biopharmaceuticals
Dermatology
Personnel
HSMN NewsFeed - 2 Dec 2011
Pfizer Completes Acquisition of Excaliard
Biopharmaceuticals
Mergers & Acquisitions
HSMN NewsFeed - 22 Nov 2011
Pfizer to Acquire Excaliard Pharmaceuticals
Biopharmaceuticals
Mergers & Acquisitions
HSMN NewsFeed - 10 Oct 2008
Excaliard Pharmaceuticals Appoints Lincoln Krochmal, MD, President & Chief Executive Officer and Jeffrey Jenson, Head of Clinical Operations.
Biopharmaceuticals
Dermatology
Personnel
HSMN NewsFeed - 24 Jul 2007
OREXIGEN(TM) Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of EMPATIC(TM) to Treat Obesity
Biopharmaceuticals
HSMN NewsFeed - 22 Nov 2006
OREXIGEN(TM) Therapeutics Completes $30 Million Series C Financing
Biopharmaceuticals
Venture Capital
HSMN NewsFeed - 22 Oct 2006
OREXIGEN(TM) Therapeutics Reports Positive Phase II Results for Excalia(TM) Combination-Therapy to Treat Obesity
Biopharmaceuticals
HSMN NewsFeed - 4 Oct 2006
OREXIGEN(TM) Therapeutics Expands Senior Management Team as Lead Products Advance Through Late-Stage Clinical Trials
Biopharmaceuticals
Personnel
HSMN NewsFeed - 24 May 2006
OREXIGEN(TM) Therapeutics Appoints Graham Cooper as Chief Financial Officer
Biopharmaceuticals
Personnel
Return to NewsFeed
